Compugen, a small biotech company but a key player in efforts to bring TIGIT immunotherapies to market, is confident of its pipeline despite setbacks to Roche’s work in the field.
The Israel-headquartered company has its own TIGIT targeting candidate COM902 in Phase I studies, alongside COM701, which targets another immune
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?